📰 Williamb Pearse News

Williamb Pearse News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Williamb Pearse. Real-time updates on events, politics, business and more.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

April 19, 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

San Diego United States Williamb Pearse University Of California San Diego School Of Medicine San Diego School

Source: onclive.com

Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL

February 20, 2024

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

United States San Diego Williamb Pearse University Of California San Diego School Of Medicine San Diego School

Source: onclive.com

Dr Pearse on the Use of BTK Inhibitors in Relapsed/Refractory MCL

January 26, 2024

William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

San Diego United States Williamb Pearse San Diego School Of Medicine University Of California San Diego School

Source: onclive.com

Pirtobrutinib Expands MCL Armamentarium, Although Sequencing Questions Remain

January 25, 2024

William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.

San Diego United States Williamb Pearse Uc San Diego School Of Medicine Diego School Fda Approval Of Pirtobrutinib

Source: onclive.com

BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

January 24, 2024

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

San Diego United States Williamb Pearse University Of California San Diego School Of Medicine San Diego School

Source: onclive.com